Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
01/15/2021 01/18/2021 01/19/2021 01/20/2021 01/21/2021 Date
1662 1661.5 1660.5 1678 1717.5 Last
4338600 2319800 2946600 4738300 5059000 Volume
+0.45% -0.03% -0.06% +1.05% +2.35% Change
Financials
Sales 2021 1 272 B 12 285 M 12 285 M
Net income 2021 181 B 1 749 M 1 749 M
Net cash position 2021 440 B 4 250 M 4 250 M
P/E ratio 2021 17,3x
Yield 2021 2,45%
Sales 2022 1 340 B 12 947 M 12 947 M
Net income 2022 219 B 2 114 M 2 114 M
Net cash position 2022 539 B 5 210 M 5 210 M
P/E ratio 2022 14,4x
Yield 2022 2,64%
Capitalization 3 190 B 30 811 M 30 814 M
EV / Sales 2021 2,16x
EV / Sales 2022 1,98x
Nbr of Employees 15 883
Free-Float 99,2%
More Financials
Company
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%). 
Sector
Pharmaceuticals
Calendar
01/29Earnings Release
More about the company
Notations Surperformance© of Astellas Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ASTELLAS PHARMA INC.
01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
AQ
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
AQ
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
MT
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
AQ
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
AQ
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
AQ
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
AQ
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
RE
2020Japanese shares slip back as investors look to U.S. stimulus debate
RE
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
MT
2020Astellas Receives Approval of EVRENZO in Japan for the Treatment of Anemia of..
AQ
2020Astellas Europe Transfers DIFICLIR Market Authorizations in EMEA, Select CIS ..
MT
2020Astellas Pharma Gets Approval for EVRENZO in Japan
MT
2020ASTELLAS PHARMA : Launches a 'Contact for Potential Acquisition of ' R&D Program..
AQ
2020Japan shares fall as virus surge, firmer yen weigh
RE
More news
News in other languages on ASTELLAS PHARMA INC.
2020TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in ribasso dopo allarme virus massimo ..
2020TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in ribasso, peggiore calo settimanale ..
2020ASTELLAS PHARMA INC. : publication des résultats semestriels
2020ASTELLAS PHARMA INC. : Veröffentlichung des Halbjahresergebnisses
2020Borsa Tokyo in calo su aumento casi virus in Europa
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 717,50 JPY
Spread / Highest target 110%
Spread / Average Target 32,1%
Spread / Lowest Target -3,93%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.7.75%30 082
JOHNSON & JOHNSON3.18%427 472
ROCHE HOLDING AG3.56%308 129
NOVARTIS AG2.82%219 666
MERCK & CO., INC.0.81%208 627
PFIZER INC.-0.84%202 881